Compare Cytokinetics Inc (CYTK) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? Cytokinetics Inc trades at $82.26 (market cap $11.12B), while Norwegian Cruise Line Holdings Ltd trades at $19.91 (market cap $8.93B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Cytokinetics Inc is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| CYTK | NCLH | |
|---|---|---|
Market Cap | $11.12B | $8.93B |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $26.94 |
52-Week Low | $33.23 | $14.79 |
Enterprise Value | $11.59B | $23.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Norwegian Cruise Line Holdings (NCLH) trades at $19.63, up 0.1% on the day, with a neutral technical signal and strong analyst consensus. Recent earnings beats and a 55.55% buy rating from analysts support optimism, though the stock faces headwinds from high debt levels and volatile cash flows. Revenue growth has improved from $4.8B in 2022 to $9.83B in 2025, but net margins remain modest at 4.3%.
The outlook is cautiously positive, with a consensus price target of $21.71 offering ~11% upside. Key opportunities include falling energy costs and robust booking trends, while risks involve elevated leverage and macroeconomic sensitivity. Investors should weigh solid fundamentals against balance sheet constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
